Advertisement

New requirements for phase I trials: a challenge for Italian clinical research

Abstract

Background

In 2015, the Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA) issued the Determination 809/2015 with new requirements for phase I clinical trials. Before it came into force, we explored the extent to which several Italian oncology centers were working to implement it.

Methods

A survey was conducted among 80 Italian centers involved in clinical trials. Investigators and research coordinators were surveyed.

Results

Answers from 42 institutions were collected: among them 88.1% were involved in oncology research. In the last 5 years, 55% had conducted from 1 to 5 phase I trials, and only 16.7% more than 5. A third were involved in not-first-in-human research and none with healthy volunteers. The majority (57.1%) of the centers did not run any projects and trials are non-commercial, and about 35%, no more than 2. While 9.5% already met the standards for self-certification, 71.4% were working to achieve them. Standard operating procedures dedicated to research and the required good clinical practice training had been established by 57.1% and 76.2%, respectively. Fifty percent of laboratories were almost compliant with the Determination. After 10 months from its coming into force, 98 sites had applied for certification, of which 34 were oncology units.

Conclusions

The new AIFA Determination imposes a certified organizational model on units and laboratories involved in phase I trials. Our results showed that great efforts were made to qualify for phase I research suggesting that other oncology units will apply for certification in the near future. Predictably, Italy will set the pace as a highly qualified country in which to conduct early-phase research.

Post author correction

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000668

Authors

Emanuela Marchesi, Manuela Monti, Oriana Nanni, Lisette Bassi, Martina Piccinni-Leopardi, Celeste Cagnazzo

Article History

Disclosures

Financial support: No grants or funding have been received for this study.
Conflict of interest: The authors declare that they have no competing interests.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  •  Scientific Direction, Rizzoli Orthopedic Institute, Bologna - Italy
  •  Italian Sarcoma Group, Bologna - Italy
  •  Meldola Scientific Institute for Research and Care, Meldola (Forlì-Cesena) - Italy
  •  Clinical Research Office, Candiolo Cancer Institute–Piemonte Foundation for Oncology, Scientific Institutes for Research and Care, Candiolo (Turin) - Italy
  •  Chemotherapy Unit, Rizzoli Orthopedic Institute, Bologna - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.